共 166 条
[1]
Dekker E(2019)Colorectal cancer Lancet 394 1467-1480
[2]
Tanis PJ(2017)Global patterns and trends in colorectal cancer incidence and mortality Gut 66 683-691
[3]
Vleugels JLA(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019
[4]
Kasi PM(2014)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 1065-1075
[5]
Wallace MB(2010)Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 4697-4705
[6]
Arnold M(2014)Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer N Engl J Med 371 1609-1618
[7]
Sierra MS(2014)Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer Ann Oncol 25 1346-1355
[8]
Laversanne M(2011)Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011-2019
[9]
Soerjomataram I(2017)Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial JAMA 317 2392-2401
[10]
Jemal A(2020)Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond Target Oncol 15 11-24